Amplo Biotechnology
Cell & Gene Therapy · Biotechnology
$2.2Mtotal raised · 7 rounds on record
Seedlatest round · Oct 2021 · 5 yr ago
$6.2Mgrants · 5 grants · CORDIS
10+team · employees, estimated range
Overview
Amplo is developing gene therapies (AAV) for diseases affecting the neuromuscular junction (e.g. congenital myasthenia, ALS, ageing, myasthenia gravis).
Funding and backers
Total raised
$2.2M
7 rounds on record
Latest round
Seed
Oct 2021 · 5 yr ago
Team
11-50
employees, estimated range
Grants
$6.2M
5 grants · CORDIS
The money's age
Long since its last round
61 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 1, 2025
Won a grant $601k · CORDIS
Sep 13, 2024
Won a grant $3M · CORDIS
Jun 1, 2023
Won a grant $700k · CORDIS
Jun 1, 2022
Won a grant $1.6M · CORDIS
Oct 6, 2021
Raised a round Seed · PRNewswire
Sep 15, 2021
Won a grant $254k · CORDIS
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Mar 2025 | $601k | — | CORDIS |
| Grant | Sep 2024 | $3M | — | CORDIS |
| Grant | Jun 2023 | $700k | — | CORDIS |
| Grant | Jun 2022 | $1.6M | — | CORDIS |
| Seed | Oct 2021 | — | — | PRNewswire |
| Venture round | Sep 2021 | $2.2M | — | SEC Form D |
| Grant | Sep 2021 | $254k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Amplo Biotechnology, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Paul HawkinsExecutive Officer, DirectorSEC Form D
Patricio SepulvedaExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Focalis Bio is developing precision gene therapies to treat focal refractory epilepsy and help patients achieve seizure freedom.
Instant Quantification of genetic modifications for Cell and Gene Therapies.
Benefits platform for cell and gene therapies designed to provide sustainable access to life-saving medicines.
Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies…
At Viralgen, we're proud to be known for just one thing: Being a world leader in AAV-based gene therapy manufacturing.. We're all in on…
Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to…
People
Paul Hawkins
Executive Officer, Director
Patricio Sepulveda
Executive Officer, Director
Jean Kim
Director
Terry Vance
Director
Daniel Bradbury
Director
Matthew Pauls
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency - PR Newswire APAC
SAN DIEGO, May 29, 2023 /PRNewswire/ -- Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency
Read more
Report
AMP-101 Shows Pharmacologic and Safety Promise for Neuromuscular Disorders in Preclinical Study CGTlive
The Amplo Biotechnology gene therapy showed positive findings in mouse models, suggestive of the therapy's development for use in a clinical setting. The AAV therapy delivers DOK7 gene, which has shown benefit in neuromuscular disorders.
Read more
Report
Amplo Biotechnology Closes Series Seed Financing to Advance Gene Therapies for The Treatment of Neuromuscular Junction Disorders
/PRNewswire/ -- Amplo Biotechnology, a privately held US-based biotech focused on developing AAV (Adeno-associated Virus)-based gene therapies for diseases...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Towson
United States
HQ
10-50 est. staff